Is Cyclotetrasiloxane safe in cosmetics?
Cyclotetrasiloxane has a safety rating of "POOR" in our database. EU status: restricted. US status: permitted. 10 toxicological study endpoint(s) are available in our database.
Also known as: Cyclotetrasiloxane, octamethyl-, D4, BRN 1787074, EINECS 209-136-7, Silicone SF 1173 (+6 more)
INCI: CYCLOTETRASILOXANE
Cyclotetrasiloxane (CAS 556-67-2) is a cosmetic cosmetic ingredient functioning as solvent, volatile carrier, conditioning agent. NOAEL 17.8 mg/kg bw/day (PDF-verified against ToxValDB ECHA IUCLID); EU Regulation 1223/2009 status: restricted, max ≥0.1% w/w prohibited in all consumer and professional products under EU Reg 2024/1328; enforcement June 6, 2026. Industrial safety data is also available in the chemical safety database. Same-CAS public records also appear in industrial chemical safety and pharmaceutical data.
View industrial chemical safety profile for CAS 556-67-2 →
Cyclotetrasiloxane is classified GHS CMR hazard (H226, H361, H413) in the chemicals database but is restricted in EU cosmetics at max ≥0.1% w/w prohibited in all consumer and professional products under EU Reg 2024/1328; enforcement June 6, 2026.
Source: Cosmetics: ingredients.eu_status/eu_max; Chemicals: ghs_classifications.signal_word/hazard_statement_code
For full compliance data across multiple jurisdictions, use the Substance Compliance tool.
Margin of Safety, dermal absorption, and sensitization profile summaries for Cyclotetrasiloxane.
Calculate MoS for your specific formulation with the MoS Calculator.
10 study endpoints found for Cyclotetrasiloxane. NOAEL (No Observed Adverse Effect Level) values are used to calculate the Margin of Safety per SCCS methodology.
| Endpoint | Value | Route | Species | Study Type | Source |
|---|---|---|---|---|---|
| NOAEL | =0.1 mg/kg bw/day | dermal | rat | dermal absorption | SCCS_vision_codex |
| NOAEL | =0.1 mg/kg bw/day | dermal | rat | dermal absorption | SCCS_vision_codex |
| NOAEL | =0.1 mg/kg bw/day | dermal | rat | dermal absorption | SCCS_vision_codex |
| NOAEL | =0.1 mg/kg bw/day | dermal | rat | dermal absorption | SCCS_vision_codex |
| NOAEL | =0.2 mg/kg bw/day | oral | rat | NOAEL study | SCCS_vision_codex |
| NOAEL | =0.2 mg/kg bw/day | oral | rat | NOAEL study | SCCS_vision_codex |
| NOAEL | =0.2 mg/kg bw/day | oral | rat | NOAEL study | SCCS_vision_codex |
| NOAEL | =0.2 mg/kg bw/day | oral | rat | NOAEL study | SCCS_vision_codex |
| NOAEL | =17.8 mg/kg bw/day | oral | rat | NOAEL study | SCCS_vision_codex |
| NOAEL | =17.8 mg/kg bw/day | oral | rat | NOAEL study | SCCS_vision_codex |
Globally Harmonized System classification per ECHA C&L inventory and ILO/WHO International Chemical Safety Cards.
Pre-calculated NOAEL → SED → MoS audit trail for Cyclotetrasiloxane across SCCS product categories, with measured dermal absorption where available.
9 toxicity values from EPA ToxValDB (aggregated from CCTE, HPV, ToxRefDB, IRIS, and other regulatory dossiers).
| Endpoint | Value | Species | Route | Duration | Source |
|---|---|---|---|---|---|
| LC50 | =36 mg/L | Rat | inhalation | - | ChemIDplus |
| LD50 | =754.3 mg/kg | Rabbit | dermal | - | ChemIDplus |
| LD50 | =1540 mg/kg | Rat | oral | - | ChemIDplus |
| LD50 | =1770 mg/kg | Rat | dermal | - | ChemIDplus |
| LEL | =250 mg/kg-day | Rat | oral | short-term | Uterotrophic Hershberger DB |
| LEL | =250 mg/kg-day | Mouse | oral | short-term | Uterotrophic Hershberger DB |
| LEL | =1000 mg/kg-day | Mouse | oral | short-term | Uterotrophic Hershberger DB |
| LEL | =849.212 mg/m3 | Rat | inhalation | chronic (developmental) | EPA TSCA 8e |
| LEL | =8492.12 mg/m3 | Rat | inhalation | chronic (developmental) | EPA TSCA 8e |
Legally binding harmonized classification per Regulation (EC) No 1272/2008 (CLP) Annex VI.
Inserted via ATP: ATP15
Cross-referenced EDC classifications, mechanism data, and dose-response evidence from EDLists, SIN List, and cosmetic-specific detail sources.
Source list: III
weak agonist
| Endpoint | Target | Value | Direction |
|---|---|---|---|
| dermal_SC_cumulative | skin | 27.5 µg/cm²/24h | - |
| dermal_epidermis_cumulative | skin | 6.4 µg/cm²/24h | - |
| dermal_absorption_range | skin | 0.1–8.1% % | - |
| Competitive ER binding; prolactin release from GH3 | ER | EC50/IC50: EC50 binding ~10^-5 M; GH3 prolactin response >=10 uM; LOEC: 10 uM; NOEC: 1 uM mixed | agonist (weak) |
European Chemicals Agency REACH dossier and Substances of Very High Concern listing.
European Commission CosIng database Annex references per Regulation (EC) No 1223/2009.
Additional regulatory detail beyond the 7-jurisdiction summary: Saudi SFDA, Korea MFDS, ASEAN ACD, Japan/Korea, Brazil/India, and cross-jurisdictional restriction entries.
| Jurisdiction | Status | Max % | Product Type |
|---|---|---|---|
| AU | restricted | 8.7 | cosmetics |
| ID | banned | - | All cosmetic products prohibited |
| ID | banned | 0% | All cosmetic products |
| TH | banned | 0% | All cosmetic products |
Cross-database dermal penetration: EPA Dryad physics-based, Roberts Mendeley permeation, and SCCS-aggregated measured values.
| Type | DA % | Method | Skin Model | SCCS Ref |
|---|---|---|---|---|
| measured_sccs_opinion | 0.94% | - | - | SCCP/0893/05 |
1 property record from structured ingredient metadata.
Expert safety assessment and concern-level summary for Cyclotetrasiloxane.
Public NOAEL study rows linked to Cyclotetrasiloxane by CAS number or substance name.
Units vary across source rows: mg/kg, mg/kg bw, mg/kg bw/day
| Absorption % | Method | Vehicle |
|---|---|---|
| 0.94% | SCCS PDF direct extraction | - |
Same-CAS public records found in pharmaceutical data.
Same-CAS rows from the pharmaceutical spoke database.
Cyclotetrasiloxane has a safety rating of "POOR" in our database. EU status: restricted. US status: permitted. 10 toxicological study endpoint(s) are available in our database.
Cyclotetrasiloxane EU regulatory status: restricted. Maximum allowed concentration: ≥0.1% w/w prohibited in all consumer and professional products under EU Reg 2024/1328; enforcement June 6, 2026. This is based on EU Regulation 1223/2009 and its amendments.
Cyclotetrasiloxane functions as: solvent, volatile carrier, conditioning agent. It is classified as a cosmetic ingredient in our database. CAS number: 556-67-2.
The NOAEL (No Observed Adverse Effect Level) for Cyclotetrasiloxane is =0.1 mg/kg bw/day based on a dermal absorption study via dermal route in rat. A total of 10 study endpoints are available. Source: SCCS_vision_codex.
Cyclotetrasiloxane also appears in industrial chemical safety and pharmaceutical data. The cross-vertical cards on this page render same-CAS public rows from the matched databases.
Cyclotetrasiloxane is classified GHS CMR hazard (H226, H361, H413) in the chemicals database but is restricted in EU cosmetics at max ≥0.1% w/w prohibited in all consumer and professional products under EU Reg 2024/1328; enforcement June 6, 2026.
Check Cyclotetrasiloxane compliance across multiple jurisdictions:
Scan any product label with Piro — our free ingredient scanner. Point your camera at the ingredients list and get instant safety scores for every ingredient.
Try Piro Free →Paste any INCI list into the Decoder for instant safety analysis, or calculate the Margin of Safety for Cyclotetrasiloxane in your formulation.